A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
PHASE1CompletedINTERVENTIONAL
Enrollment
64
Participants
Timeline
Start Date
January 3, 2023
Primary Completion Date
March 31, 2023
Study Completion Date
April 3, 2023
Conditions
Healthy
Interventions
DRUG
Lazertinib
Lazertinib will be administered orally.
Trial Locations (1)
85283
Celerion, Tempe
All Listed Sponsors
lead
Janssen Research & Development, LLC
INDUSTRY
NCT05742594 - A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter